# Satsuma Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/satsuma-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.satsumarx.com
- Total disclosed funding: $68M
- Latest round: Series B (Apr 24, 2019)
- Investors on record: 11

## About

Based in California, US, and founded in 2016 by President and CEO John Kollins, Satsuma Pharmaceuticals, Inc. aka Satsuma Pharmaceuticals, operates as a biopharmaceutical company that develops STS101, that is a novel and proprietary investigational drug-device combination product specifically designed to allow intranasal administration of the anti-migraine drug dihydroergotamine (DHE). The company is a publicly-traded company on NASDAQ by STSA and the employee count was 21. In April 2019, Satsuma Pharmaceuticals, Inc. raised USD 62 million in series B funding led by Wellington Management Company, with participation from Osage University Partners, CAM Capital, Surveyor, Eventide Asset Management, Cormorant, Lumira Ventures, and SBI Investment. RA Capital Management, TPG Biotech, and Shin Nippon Biomedical Laboratories also participated in the round. 

The company develops STS101 which is prepared by combining Satsuma powder technology with a nasal delivery device that is used for acute treatments for migraine. The firm offers a proprietary dry-powder formulation that is a mucoadhesive drug carrier and engineered drug particle technologies. Satsuma Pharmaceuticals provide a nasal delivery device that is its proprietary product. STS101 is evaluated in Phase 3 clinical trials for the acute treatment of migraine.

## Funding rounds

- Series B, Apr 24, 2019, $62M — OUP (Osage University Partners), Wellington Management, TPG Biotech, Surveyor Capital, CAM Capital, SBI Investment, RA Capital Management, Cormorant Asset Management, Eventide Asset Management, Shin Nippon Biomedical Laboratories, LTD., Lumira Ventures
- Series A, Dec 16, 2016, $6M — TPG Biotech, RA Capital Management, Shin Nippon Biomedical Laboratories, LTD.

## Investors

- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Shin Nippon Biomedical Laboratories, LTD. — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Surveyor Capital — Series B
- CAM Capital — Series B
- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series B
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series B